Low dose endoluminal photodynamic therapy improves murine T cell-mediated colitis.

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: de l'auteur⸱e
ID Serval
serval:BIB_5D5A35108330
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Low dose endoluminal photodynamic therapy improves murine T cell-mediated colitis.
Périodique
Endoscopy
Auteur⸱e⸱s
Favre Laurent, Borle François, Velin Dominique, Bachmann Daniel, Bouzourene Hanifa, Wagnieres Georges, van den Bergh Hubert, Ballabeni Pierluigi, Gabrecht Tanja, Michetti Pierre, Schreiber Stefan, Ortner Maria-Anna
ISSN
1438-8812 (Electronic)
ISSN-L
0013-726X
Statut éditorial
Publié
Date de publication
2011
Peer-reviewed
Oui
Volume
43
Numéro
7
Pages
604-616
Langue
anglais
Résumé
BACKGROUND AND STUDY AIMS: Low dose photodynamic therapy (LDPDT) may modify the mucosal immune response and may thus provide a therapy for Crohn's disease. We evaluated the efficacy and safety of this technique in a murine T cell-mediated colitis model. METHODS: The safety of LDPDT was first tested in BALB/c mice. Naïve T cells were used to induce colitis in mice with severe combined immunodeficiency, which were followed up endoscopically, and a murine endoscopic index of colitis (MEIC) was developed. The efficacy of LDPDT (10 J/cm (2); delta-aminolevulinic acid, 15 mg/kg bodyweight) was then tested on mice with moderate colitis, while a disease control group received no treatment. The MEIC, weight, length, and histology of the colon, cytokine expression indices, number of mucosal CD4 (+) T cells, percentage of apoptotic CD4 (+) T cells, body weight, and systemic side effects were evaluated. RESULTS: LDPDT improved the MEIC ( P = 0.011) and the histological score ( P = 0.025), diminished the expression indices of the proinflammatory cytokines, interleukin-6 ( P = 0.042), interleukin-17 ( P = 0.029), and interferon-gamma ( P = 0.014), decreased the number of mucosal CD4 (+) T cells, and increased the percentage of apoptotic CD4 (+) T cells compared with the disease control group. No local or systemic side effects occurred. CONCLUSION: LDPDT improves murine T cell-mediated colitis, decreases the proinflammatory cytokines interleukin-6, interleukin-17, and interferon-gamma, and decreases the number of CD4 (+) T cells. No adverse events were observed. Therefore, this technique is now being evaluated in patients with inflammatory bowel disease.
Pubmed
Web of science
Création de la notice
01/06/2011 11:03
Dernière modification de la notice
20/08/2019 15:15
Données d'usage